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Background
Chemoradiation based on weekly cisplatin is the standard
treatment for locally advanced cervical cancer; however,
the nephrotoxic potential and the requirement for hydra-
tion of cisplatin somewhat restrains its use. We previously
reported that the recommended dose of carboplatin to be
used weekly with radiation was 133 mg/m2  (IJROBP
2003). Hence, we wanted to analyze our results of treat-
ment with carboplatin chemoradiation which was
adopted as routine treatment in our Institution for
patients having high risk conditions to develop renal dys-
function by cisplatin.
Materials and methods
We reviewed the files of 85 patients with locally advanced
cervical cancer who received radiation plus weekly carbo-
platin. The three main conditions that dictated the use of
carboplatin instead of cisplatin in the patients analyzed
were diabetes mellitus, high blood pressure and/or >70
years old. Treatment compliance, response rate and sur-
vival were analyzed.
Results
A total of 85 patients who received radiation and carbopl-
atin were analyzed. Mean age was 58 years (range, 27–79
years). The majority of cases were squamous cell carci-
noma (94%), and distribution according to International
Federation of Gynecology and Obstetrics (FIGO) stage
was as follows: IB2, 4.7%, IIA, 8.2%; IIB, 41.1%, IIIA,
4.7% and IIIB, 38.8%; there were only two IVA cases
(2.5%). Overall, 93% of patients completed external
beam, and intracavitary low-dose rate brachytherapy. The
majority of patients received five and six courses of weekly
carboplatin, 40% and 38.8% respectively. Complete
responses were achieved in 72 (84.7%) patients, whereas
5 patients (5.8%) had persistent and 8 (9.4%) progressive
disease. At median follow-up (20.8 months; range, 5–45
months) overall survival is 81.7%.
Conclusion
Our results support the use of chemoradiation with six
weekly applications of carboplatin at 133 mg/m2 during
external radiation for routine management of locally
advanced cervical cancer in patients who present high risk
factors to develop renal dysfunction.
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